# ArriVent BioPharma, Inc.

**AVBP**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001868279


# None

### No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $333.2M |
| **Warnings** | dilution, thin data<br>not computable: degenerate inputs, fortress balance sheet |
| **Inputs computable** | 4 of 13 |
| **Graded from** | filings received through Mar 5, 2026<br>257 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026 |
| **Last close** | $11.57<br>2026-11-16; market equity $598.7M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 5, 2026*

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team's deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 (MRG007), through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 77.1** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (1.9%) | (6.7%) | 77.1 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 9.6** | | | | | |
| Altman Z double-prime | 10.94 | 0.31 | 8.5 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 12.83x | 2.68x | 10.8 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 67.3** | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *four consecutive annual FCF observations are required; found 0* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | not computable | 3.2% | | | |
| *four annual observations are required; found 2* | | | | | |
| Net share issuance, one year | 29.9% | 1.6% | 67.3 | 624 | 2026-03-04 |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 29.9% |
| Thin data | 4 of 13 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-16 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 61.7% | (1.7%) | 83 |
| Distance from 52-week high | (66.7%) | (31.5%) | 16 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | not computable | 0.5% | |
| Book value to price | 0.66 | 0.28 | 75 |
| Sales to price | not computable | 0.36 | |
| Composite equity issuance, five years | not computable | 13.2% | |
| Relative strength against the sector, log excess return | 0.31 | (0.19) | 83 |
| Twelve-month failure probability, CHS model | 0.15% | 0.06% | 71 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $113.6M |
| Operating cash flow, four quarters | -$152.8M |
| Months of runway | 8.9 |
| Days since last periodic filing | 8 (10-Q received Nov 9, 2026) |
| Median daily dollar volume, 63 sessions | $16.0M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$166.3M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$160.6M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 3 | assets | us-gaap:Assets | $333.2M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 4 | assets | us-gaap:Assets | $274.9M | 2024-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 5 | current assets | us-gaap:AssetsCurrent | $332.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $25.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$404.6M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$177.5M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 9 | book equity | us-gaap:StockholdersEquity | $307.2M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 10 | liabilities | us-gaap:Liabilities | $25.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-024127 |
| 11 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 44,201,622 | 2026-03-04 | 2026-03-05 | 10-K | 26-024127 |
| 12 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 34,016,197 | 2025-02-28 | 2025-03-03 | 10-K | 25-001999 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.